Immunosuppressive therapies for COVID-19 treatment COVID19 SARSCoV2 Coronavirus ImmunosuppressiveTherapy
By Bhavana KunkalikarAug 31 2022Reviewed by Aimee Molineux In a recent study published in the PLoS ONE journal, researchers assessed the impact of baricitinib, netakimab, and tocilizumab against coronavirus disease 2019 .
The team performed the present observational cohort study in COVID-19 care units at two tertiary hospitals in Moscow on patients diagnosed with mild or moderate SARS-CoV-2-associated pneumonia. The study cohort included patients who were adults having reverse transcription-polymerase chain reaction -confirmed COVID-19 who were hospitalized between February 2020 and August 2020.
Results Related StoriesThe study results showed that 154 patients having mild-to-moderate SARS-CoV-2 infections were eligible to receive the combination of SOC therapy with baricitinib, netakimab, or tocilizumab, or only SOC therapy without the receipt of any targeted immunosuppression. The number of patients with mild to moderate COVID-19 was similar across all the groups, with a considerable difference noted in the initial NEWS2 scores for tocilizumab compared to the netakimab-treated cohort.
Danmark Seneste Nyt, Danmark Overskrifter
Similar News:Du kan også læse nyheder, der ligner denne, som vi har indsamlet fra andre nyhedskilder.
What lessons can we learn from the COVID-19 pandemic for HIV?A new study discussed how experiences from the coronavirus disease 2019 (COVID-19) pandemic could be leveraged for human immunodeficiency virus (HIV).
Læs mere »
What lessons can we learn from the COVID-19 pandemic for HIV?A new study discussed how experiences from the coronavirus disease 2019 (COVID-19) pandemic could be leveraged for human immunodeficiency virus (HIV).
Læs mere »
Toddler grinding teeth: Causes, symptoms and treatmentIf you're wondering why your toddler is grinding their teeth, we've rounded up the possible causes, symptoms and treatments.
Læs mere »